Provided by Tiger Trade Technology Pte. Ltd.

Replimune Group Inc.

13.07
-0.3800-2.83%
Post-market: 13.200.1262+0.97%19:54 EDT
Volume:1.30M
Turnover:17.12M
Market Cap:1.23B
PE:-4.14
High:13.83
Open:13.69
Low:12.80
Close:13.45
52wk High:16.33
52wk Low:1.50
Shares:94.22M
Float Shares:77.49M
Volume Ratio:0.48
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1550
EPS(LYR):-3.3828
ROE:-134.29%
ROA:-51.30%
PB:11.66
PE(LYR):-3.86

Loading ...

Replimune Group Is Maintained at Neutral by Wedbush

Dow Jones
·
Jun 01

Replimune Group trading halted, volatility trading pause

TIPRANKS
·
Jun 01

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM

Reuters
·
Jun 01

Replimune price target raised to $6 from $2 at Wedbush

TIPRANKS
·
Jun 01

Replimune Says Evaluating RP2 for Metastatic Uveal Melanoma in Phase 2/3 Trial; Shares Up Pre-Bell

MT Newswires Live
·
Jun 01

Replimune Group Inc : JP Morgan Raises to Neutral From Underweight

THOMSON REUTERS
·
Jun 01

Replimune presents final first-in-human data for RP2 alone, with nivolumab

TIPRANKS
·
Jun 01

Replimune presents 3-year overall survival data from IGNYTE trial

TIPRANKS
·
Jun 01

Replimune publishes RP2 Phase 1 ASCO presentation data###

Reuters
·
May 31

Replimune says RP2 plus nivolumab posts 19.1% response rate in phase 1 advanced solid tumor trial

Reuters
·
May 31

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

GlobeNewswire
·
May 31

Replimune Group - Rp1 Plus Nivolumab Achieves Median Overall Survival of 32.9 Months in Anti-Pd-1-Failed Melanoma

THOMSON REUTERS
·
May 30

Replimune reports 32.9-month median survival in IGNYTE trial of RP1-nivolumab in anti-PD-1-failed melanoma

Reuters
·
May 30

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

GlobeNewswire
·
May 30

Top News Today: Stocks Rise as Traders Await Iran Deal Confirmation

Dow Jones
·
May 30

Wedbush Adjusts Price Target on Replimune Group to $6 From $2, Maintains Neutral Rating

MT Newswires Live
·
May 30

Top Midday Gainers

MT Newswires Live
·
May 30

Why Penny Stock Replimune (REPL) Nearly Doubled Today

TIPRANKS
·
May 29

Replimune Shares Soar as FDA Reverses Course on Skin Cancer Drug Application

Stock News
·
May 29

Replimune Shares Surge 75% After Co Plans to Resubmit US Application for Skin Cancer Drug

THOMSON REUTERS
·
May 29